PYX Resources: Achieving volume and diversification milestones. Watch the video here.
Look no further than last RNSā¦clues in the text.
Avacta is at a pivotal point, having recently announced clinical data that have already begun to generate interest from potential commercial partners. I am delighted to be joining at such an exciting point in the journey of the business, to help the team optimise the commercial opportunities of their technologies and assets."
LLP, yes sets the scene a little. If thereās nil interest at present āthen Iāll go to seaāā¦
Time will set the agenda sooner rather than later I suspect.
GLA
Https://www.baybridgebio.com/biotech-ipos.html
Only quality clinical stage cosā¦..?
C, ā¦indeed potentially complex , but in this case thereās a track record ,so differ kettle of fish to some extent.
Plus fast track potential stateside etc.
GLA
DTW,
Well said ā¦new dev role brilliantly flagged the ā interestā in deals going forward @ his confirmation in role RNS.
Imminent deals will see this run ..
Regards
Current val $ 1-2bn
With deals +++ to $4/5bn +/-
Gla
Https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html
Stage 1 punt by Zeneca.
$1.2bn
Av will be notably a target when first few deals are throughā¦and they are warming up to get them in the new year.
Merry Christmas to all
VS,
I donāt see a comparator to BP, but a licensing provider generating significant rev.
Alternatively a managed sale,to which all will benefit in the AS team.
Whatās in AS mind? After a decade+ from a standing startā¦Iād suggest the alternative.
The declared ā everyone needs to benefitā can come from either but the alternative would be a simpler model. Letās seeā¦
GLA
Https://www.bio-itworld.com/news/2010/09/30/the-solexa-story
Tim ,well said
Todays VIP appointment says it allā¦
In a few months this will likely be a different prospect.
Iāll warrant a deals quite imminent as parties wonāt wish to miss the boat here.
There arenāt many like this one.
Extraordinary potential value .
Rumour aside , deal will have been discussed for months.
GLA
Interested partners etc . Good start ! Thereās a prompt if ever I saw oneā¦.
.jrdc.. have anotherā¦ deal in the way. No BPs going to miss this one .
Watch this space.
āPatience is a virtueā
But suspect padā loinā¦
On y vaā¦
gla
These data are Remarkable .
Congratulations Alastair and team.
Cf drug development where an increase in survival times , is seen as success.
Alastairs comment says it all.
Tremendous step in oncology treatment.
Exceptional news.
See last Q&A Elliot Foster for analysis via USA.
Av strategy is sound and sure . Inflection points follow.
One this week no doubt.
EF critical point.. Biotech funds will develop .
Gla
Based on M&A recent history, then
- Current value $ 2bn+|-
- with later phase and higher pot then$ 3-5bn+|-
DYOR
Good commentaryā¦.
2 āplumsā. on Wed would be
- . A positive Data set , well explained.
- ',some insight into partnering to take this forward commercially etc
GLA
.-
11/ā¦commercial strategy 5/23
AVA6000
Potentially partner phase 2 ā¦
Letās see